CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Obeticholic Acid

Last Updated: November 24, 2016
Result type: Reports
Project Number: SR0509-000
Product Line: Reimbursement Review

Generic Name: Obeticholic Acid

Brand Name: Ocaliva

Manufacturer: Intercept Pharma Canada, Inc.

Therapeutic Area: Primary Biliary Cholangitis

Indications: Primary biliary cholangitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 25, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions